Physician profile
Richard Gordon
NPI 1477649424
$9,739.33
in general payments reported to CMS, 2019-2025
13 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $655 · 2021: $895 · 2022: $1,645 · 2023: $292 · 2024: $3,620 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,338 · Travel and Lodging: $1,426 · Education: $9.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,338.42 |
| Travel and Lodging | $1,425.54 |
| Education | $9.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,968.39 | 2019-2025 | Idosetr, Idose, Istent Infinite |
| Carl Zeiss Meditec USA, INC. | $1,678.83 | 2024 | Visumax, Veracity Surgical, Cirrus Hd-Oct |
| Alcon Vision LLC | $1,279.45 | 2022-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Abbvie INC. | $1,053.73 | 2022-2025 | |
| Sight Sciences, INC. | $790.12 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ivantis, INC | $585.02 | 2019-2021 | |
| Allergan, INC. | $513.36 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $469.06 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Aerie Pharmaceuticals, INC. | $244.75 | 2019 | |
| Epizyme, INC. | $69.32 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $55.21 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $17.50 | 2025 | Vivimusta |
| Tersera Therapeutics LLC | $14.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.